DrugDashboards

Market view

efavirenz, emtricitabine and tenofovir disoproxil fumarate

9 marketed package NDCs · 7 active manufacturers

Most dispensed: 600 mg; 200 mg; 300 mg · Tablet, Film Coated · #30 tablet, film coateds/bottle

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble. The price is down 20% over the past year, to $1.16 per unit.

Price range and competition

RSS: changes for this drug

Every company selling this drug reports its own price. The line follows the middle of the pack; the shaded band holds the middle half of companies — the wider it is, the more they disagree.

$0$25.00$50.00$75.00Dec 2020Sep 202607companies actively selling

Latest · Sep 2026 — typical price $1.16 · middle half $1.16–$1.16 · full range $1.16–$1.16 · 6 products · 7 companies

middle half of companies’ pricestypical (median) pricewhat manufacturers charge wholesalers (WAMP)companies actively selling (bottom lane)Priced per unitⓘSource: CMS NADAC
ⓘ How this was built
Data sources
  • CMS NADAC weekly survey + monthly archives back to 2013 (data.medicaid.gov)
  • CMS Federal Upper Limit files (weighted AMP)
  • FDA NDC Directory (openFDA) — maker roster
Method

Each month's band spans the NADAC unit prices of every NDC of this drug (min, quartiles, median, max), split into brand and generic cohorts by FDA marketing category. Maker counts come from distinct labelers with the NDC actively listed.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

What changed in the last 90 days

Every detected change for efavirenz, emtricitabine and tenofovir disoproxil fumarate, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.

Same drug class

Other molecules FDA puts in Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.

Common questions

Is Efavirenz, emtricitabine and tenofovir disoproxil fumarate in shortage right now?
No. FDA does not currently list Efavirenz, emtricitabine and tenofovir disoproxil fumarate in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
Who makes Efavirenz, emtricitabine and tenofovir disoproxil fumarate?
7 companies have marketed Efavirenz, emtricitabine and tenofovir disoproxil fumarate in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
What does Efavirenz, emtricitabine and tenofovir disoproxil fumarate cost?
The typical pharmacy pays about $1.16 per unit, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.

All marketed products

Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.